Home › NDC Lookup › RxCUI directory › RxCUI 2204102

Ledipasvir 33.75 MG / sofosbuvir 150 MG Oral Pellet [Harvoni] — RxCUI 2204102

Name: Ledipasvir 33.75 MG / sofosbuvir 150 MG Oral Pellet [Harvoni] (RxCUI 2204102)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 2204102 Semantic branded drug · SBD ● Current RxNorm concept 4 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2204102

Official nameLedipasvir 33.75 MG / sofosbuvir 150 MG Oral Pellet [Harvoni]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known asHarvoni (ledipasvir 33.75 MG / sofosbuvir 150 MG) per packet Oral Pellets; Harvoni 33.75 MG / 150 MG per packet Oral Pellets

FDA products mapped4

Package NDCs mapped4

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Sofosbuvir: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Sovaldi works by blocking a specific enzyme the hepatitis C virus needs to copy itself. When used correctly as part of a combination treatment, many people do clear the virus compl...
What exactly does Sovaldi do — is it a cure for hepatitis C?
You can take Sovaldi with or without food — it doesn't matter. Studies showed that even a high-fat meal doesn't significantly change how much medicine gets into your system. Just t...
Can I take Sovaldi with food, or does it need to be on an empty stomach?

📖 Read our full Sofosbuvir guide →

🕸️ Concept Web — How Ledipasvir 33.75 MG / sofosbuvir 150 MG Oral Pel... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Ledipasvir 33.75 MG / sofosbuvir 150 MG Oral Pellet [Harvoni] RxCUI 2204102 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 3

The active substance itself — no strength, form, or brand attached yet.
- Ledipasvir 1591922 IN
- Sofosbuvir 1484911 IN
- Ledipasvir / sofosbuvir 1591942 MIN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Harvoni 1591944 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Ledipasvir / sofosbuvir Oral Pellet 2204094 SCDF
- Ledipasvir / sofosbuvir Oral Product 1591939 SCDG
- Ledipasvir / sofosbuvir Pellet Product 2204093 SCDG
- Ledipasvir / sofosbuvir Oral Pellet [Harvoni] 2204096 SBDF
- Harvoni Oral Product 1591947 SBDG
- Harvoni Pellet Product 2204097 SBDG
- Oral Pellet 317691 DF
- Oral Product 1151131 DFG
- +1 more in this family
Clinical & branded drugs 4

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Ledipasvir 33.75 MG / sofosbuvir 150 MG Oral Pellet 2204100 SCD
- Ledipasvir 33.75 MG 2204099 SCDC
- Sofosbuvir 150 MG 2203990 SCDC
- Ledipasvir 33.75 MG / sofosbuvir 150 MG [Harvoni] 2204101 SBDC

Showing up to 8 concepts per family — 16 of 17 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Ledipasvir 33.75 MG / sofosbuvir 150 MG Oral Pellet SCD · 2204100
Ledipasvir 33.75 MG SCDC · 2204099
Sofosbuvir 150 MG SCDC · 2203990
Ledipasvir / sofosbuvir Oral Pellet SCDF · 2204094
Ledipasvir / sofosbuvir Oral Product SCDG · 1591939
Ledipasvir / sofosbuvir Pellet Product SCDG · 2204093

Brand-Name Concepts

Ledipasvir 33.75 MG / sofosbuvir 150 MG [Harvoni] SBDC · 2204101
Ledipasvir / sofosbuvir Oral Pellet [Harvoni] SBDF · 2204096
Harvoni Oral Product SBDG · 1591947
Harvoni Pellet Product SBDG · 2204097
Harvoni BN · 1591944

📦 FDA Products & Package NDCs

4 products · 4 package NDCs

4 package NDCs map to RxCUI 2204102 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
61958-1801-01	28 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-1801-1)	Harvoni	Gilead Sciences, Inc	2014-10-10
61958-1803-01	28 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-1803-1)	Harvoni	Gilead Sciences, Inc	2019-08-28
61958-1804-01	120 PELLET in 1 PACKET (61958-1804-1)	Harvoni	Gilead Sciences, Inc	2019-08-28
61958-1805-01	90 PELLET in 1 PACKET (61958-1805-1)	Harvoni	Gilead Sciences, Inc	2019-08-28

Observed labelers: Gilead Sciences, Inc (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.